[go: up one dir, main page]

EA201692568A1 - Составы с полипептидами-рецепторами и связанные с ними способы - Google Patents

Составы с полипептидами-рецепторами и связанные с ними способы

Info

Publication number
EA201692568A1
EA201692568A1 EA201692568A EA201692568A EA201692568A1 EA 201692568 A1 EA201692568 A1 EA 201692568A1 EA 201692568 A EA201692568 A EA 201692568A EA 201692568 A EA201692568 A EA 201692568A EA 201692568 A1 EA201692568 A1 EA 201692568A1
Authority
EA
Eurasian Patent Office
Prior art keywords
compositions
related methods
polypeptides
receptors
receptors polypeptides
Prior art date
Application number
EA201692568A
Other languages
English (en)
Inventor
Кристофер Майкл Хакк
Рамиль Латыпов
Original Assignee
Санта Мария Биотерапевтикс, Инк.
Амджен Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Санта Мария Биотерапевтикс, Инк., Амджен Инк. filed Critical Санта Мария Биотерапевтикс, Инк.
Publication of EA201692568A1 publication Critical patent/EA201692568A1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/179—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1796—Receptors; Cell surface antigens; Cell surface determinants for hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/71—Receptors; Cell surface antigens; Cell surface determinants for growth factors; for growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Endocrinology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Описана композиция на основе рецептора активина IIB и связанные с ней способы применения, например способы лечения солидных опухолей. Также предложены способы получения указанных соединений и составов.
EA201692568A 2014-06-13 2015-06-15 Составы с полипептидами-рецепторами и связанные с ними способы EA201692568A1 (ru)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462012104P 2014-06-13 2014-06-13
US201462047995P 2014-09-09 2014-09-09
US201462058789P 2014-10-02 2014-10-02
US201562142812P 2015-04-03 2015-04-03
PCT/US2015/035818 WO2015192127A2 (en) 2014-06-13 2015-06-15 Formulated receptor polypeptides and related methods

Publications (1)

Publication Number Publication Date
EA201692568A1 true EA201692568A1 (ru) 2017-05-31

Family

ID=54834575

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201692568A EA201692568A1 (ru) 2014-06-13 2015-06-15 Составы с полипептидами-рецепторами и связанные с ними способы

Country Status (19)

Country Link
US (2) US20170202909A1 (ru)
EP (1) EP3155008B1 (ru)
JP (1) JP2017519009A (ru)
KR (1) KR20170035891A (ru)
CN (1) CN107074931A (ru)
AP (1) AP2016009647A0 (ru)
AU (1) AU2015274293A1 (ru)
BR (1) BR112016029211A2 (ru)
CA (1) CA2952231A1 (ru)
CL (1) CL2016003191A1 (ru)
EA (1) EA201692568A1 (ru)
IL (1) IL249373A0 (ru)
MX (1) MX2016016281A (ru)
PE (1) PE20170471A1 (ru)
PH (1) PH12016502479A1 (ru)
SG (1) SG11201610432UA (ru)
TN (1) TN2016000551A1 (ru)
TW (1) TW201625675A (ru)
WO (1) WO2015192127A2 (ru)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3269381B1 (en) 2005-11-23 2020-10-07 Acceleron Pharma, Inc. Activin-actriia antagonists in use for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
MX2009008222A (es) 2007-02-01 2009-10-12 Acceleron Pharma Inc Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama.
TW201803890A (zh) 2007-02-02 2018-02-01 艾瑟勒朗法瑪公司 衍生自ＡｃｔＲＩＩＢ的變體與其用途
TWI667038B (zh) 2007-02-09 2019-08-01 美商艾瑟勒朗法瑪公司 包含ＡｃｔＲＩＩａ-Ｆｃ融合蛋白的醫藥組合物；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防與癌症相關的骨質流失之用途；ＡｃｔＲＩＩａ-Ｆｃ融合蛋白於治療或預防多發性骨髓瘤之用途
CN101861161B (zh) 2007-09-18 2017-04-19 阿塞勒隆制药公司 活化素‑actriia拮抗剂和减少或抑制fsh分泌的用途
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
TWI626945B (zh) 2008-08-14 2018-06-21 艾瑟勒朗法瑪公司 使用ｇｄｆ阱以增加紅血球水平
US8178488B2 (en) 2009-06-08 2012-05-15 Acceleron Pharma, Inc. Methods for increasing thermogenic adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc SHORTEN ACTRIIB FC FUSION PROTEINS
EP3332796A1 (en) 2009-11-17 2018-06-13 Acceleron Pharma Inc. Actriib proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
US20150359850A1 (en) 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
US20120121576A1 (en) 2010-11-08 2012-05-17 Jasbir Seehra Actriia binding agents and uses thereof
KR20220156979A (ko) 2012-11-02 2022-11-28 셀진 코포레이션 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도
TN2016000553A1 (en) 2014-06-13 2018-04-04 Acceleron Pharma Inc Methods and compositions for treating ulcers
MX2017013520A (es) 2015-04-22 2018-05-22 Alivegen Usa Inc Nuevas proteinas hibridas de bloqueo del ligando actriib para tratar enfermedades de atrofia muscular.
KR20180128405A (ko) * 2016-02-22 2018-12-03 악셀레론 파마 인코포레이티드 면역 활성 증가에 사용하기 위한 ActRII 길항제
JOP20190085A1 (ar) 2016-10-20 2019-04-17 Biogen Ma Inc طرق علاج الضمور العضلي ومرض العظام باستخدام بروتينات احتجاز مركب ترابطي actriib هجين حديثة
CN119591692A (zh) 2016-11-10 2025-03-11 科乐斯疗法公司 激活素受体iia型变体及其使用方法
JP7188944B2 (ja) * 2017-09-07 2022-12-13 Ｊｃｒファーマ株式会社 水性医薬組成物
MX2020004151A (es) 2017-10-30 2020-08-13 Takeda Pharmaceuticals Co Detergentes compatibles con el medio ambiente para la inactivacion de virus envueltos en lipidos.
AU2018364668B2 (en) 2017-11-09 2024-05-30 Keros Therapeutics, Inc. Activin receptor type lla variants and methods of use thereof
KR20200109330A (ko) 2018-01-12 2020-09-22 케로스 테라퓨틱스, 인크. 액티빈 수용체 유형 iib 변이체 및 그의 사용 방법
CN112839639A (zh) * 2018-08-29 2021-05-25 川斯勒佰尔公司 制备负载mRNA的脂质纳米颗粒的改进方法
AR116636A1 (es) * 2018-10-12 2021-05-26 Advanced Accelerator Applications Int Sa Radiofármacos dirigidos a grpr y usos de los mismos
TWI878344B (zh) * 2019-09-17 2025-04-01 瑞士商諾華公司 放射性標記grpr拮抗劑之方法及其套組

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3773919A (en) 1969-10-23 1973-11-20 Du Pont Polylactide-drug mixtures
US4263428A (en) 1978-03-24 1981-04-21 The Regents Of The University Of California Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same
IE52535B1 (en) 1981-02-16 1987-12-09 Ici Plc Continuous release pharmaceutical compositions
DE3374837D1 (en) 1982-02-17 1988-01-21 Ciba Geigy Ag Lipids in the aqueous phase
HUT35524A (en) 1983-08-02 1985-07-29 Hoechst Ag Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance
EP0143949B1 (en) 1983-11-01 1988-10-12 TERUMO KABUSHIKI KAISHA trading as TERUMO CORPORATION Pharmaceutical composition containing urokinase
AU648505B2 (en) 1989-05-19 1994-04-28 Amgen, Inc. Metalloproteinase inhibitor
WO2000029581A1 (en) 1998-11-13 2000-05-25 Immunex Corporation Human tslp dna and polypeptides
JP4038118B2 (ja) 2002-11-29 2008-01-23 株式会社コガネイ 流体圧シリンダ
JO3324B1 (ar) * 2006-04-21 2019-03-13 Amgen Inc مركبات علاجية مجففة بالتبريد تتعلق بالعصارة الهضمية
TWI454479B (zh) * 2007-03-06 2014-10-01 Amgen Inc 變異之活動素受體多肽及其用途
JP6078217B2 (ja) * 2008-01-15 2017-02-08 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー 粉末化されたタンパク質組成物及びその作製方法
MX2011005505A (es) * 2008-11-26 2011-09-01 Amgen Inc Variantes de polipeptidos receptores de activina iib y aplicaciones de estos.
US20150359850A1 (en) * 2009-11-25 2015-12-17 Santa Maria Biotherapeutics, Inc. Administration of an anti-activin-a compound to a subject
WO2011141926A2 (en) * 2010-05-10 2011-11-17 Intas Biopharmaceuticals Limited Liquid formulation of polypeptides containing an fc domain of an immunoglobulin
JP5782185B2 (ja) 2012-06-01 2015-09-24 日本電信電話株式会社 パケット転送処理方法およびパケット転送処理装置
US9300829B2 (en) 2014-04-04 2016-03-29 Canon Kabushiki Kaisha Image reading apparatus and correction method thereof
WO2016205370A1 (en) * 2015-06-15 2016-12-22 Santa Maria Biotherapeutics, Inc. Methods of using activin receptor iib-based proteins

Also Published As

Publication number Publication date
EP3155008B1 (en) 2020-08-26
AU2015274293A1 (en) 2017-02-02
WO2015192127A3 (en) 2016-03-17
US20240277805A1 (en) 2024-08-22
KR20170035891A (ko) 2017-03-31
PH12016502479A1 (en) 2017-04-10
JP2017519009A (ja) 2017-07-13
MX2016016281A (es) 2017-03-31
US20170202909A1 (en) 2017-07-20
EP3155008A4 (en) 2018-05-16
CL2016003191A1 (es) 2017-11-10
SG11201610432UA (en) 2017-01-27
CN107074931A (zh) 2017-08-18
EP3155008A2 (en) 2017-04-19
WO2015192127A2 (en) 2015-12-17
PE20170471A1 (es) 2017-05-14
IL249373A0 (en) 2017-02-28
BR112016029211A2 (pt) 2018-01-30
CA2952231A1 (en) 2015-12-17
AP2016009647A0 (en) 2016-12-31
TW201625675A (zh) 2016-07-16
TN2016000551A1 (en) 2018-04-04

Similar Documents

Publication Publication Date Title
EA201692568A1 (ru) Составы с полипептидами-рецепторами и связанные с ними способы
CY1125032T1 (el) Υποκινητης mnd χιμαιρικους υποδοχεις αντιγονου
MX383917B (es) Nuevos péptidos que se unen al ligando-1 de muerte programada (pd-l1) para formación de imagen.
MX2020009649A (es) Anticuerpos monoclonales contra bcma.
SI3394094T1 (sl) T celični receptorji, specifični za NY-ESO-1 tumorski kompleks antigen-HLA-A*02
MX2019007021A (es) Anticuerpos il-11ra.
IL263497B (en) 1-tetrahydropyranylcarbonyl-3,2-dihydro-h1-indole compounds for cancer treatment
ECSP17044494A (es) Receptores de antígenos quiméricos de bcma
MX2017003478A (es) Anticuerpos anti-fgfr2/3 y metodos para su uso.
EA201791117A1 (ru) Частичные агонисты инсулинового рецептора
PH12017501748B1 (en) Antibodies to icos
LT3594238T (lt) Antikūno kompozicijos, skirtos navikų gydymui
EA201691991A1 (ru) Мультиспецифические антитела
EA201790545A1 (ru) Антитела и иммуноконъюгаты против her2
SG10201803042PA (en) Anti-tim-3 antibodies
WO2016014789A3 (en) Bcma chimeric antigen receptors
SG10201909716RA (en) Modified j-chain
EA201791421A1 (ru) Антитела против csf1r для лечения pvns
CY1125153T1 (el) Νεα ετεροκυκλικα αντiοιστρογονα
WO2015200534A3 (en) Small molecule agonists of neurotensin receptor 1
EA201591709A1 (ru) 5-бром-индирубины
EA201790373A1 (ru) Способы получения модуляторов toll-подобных рецепторов
IL248807B (en) Kv1.3 potassium channel antagonists
EA201991576A1 (ru) Частичные агонисты инсулинового рецептора
CR20160585A (es) Polipéptidos receptores formulados y métodos relacionados